Inclusion Criteria:

1. Patients with histologically or cytologically confirmed refractory or relapsed Mantle
Cell Lymphoma (at initial diagnosis or relapse),

2. Ann Arbor Stage I-IV with at least one tumor site measurable,

3. Patients who received prior therapy (at least one but no more than three lines
therapies) for Mantle Cell Lymphoma (MCL),

4. Aged ≥ 18 years,

5. ECOG performance status 0, 1 or 2,

6. Adequate hepatic and renal function :

- Serum Glutamic Oxaloacetic Transaminase (SGOT)/AST or Serum Glutamic Pyruvic
TransaminaseSGPT/ALT ≤ 3.0 x upper limit of normal (ULN),

- Serum Total Bilirubin ≤ 1.5 mg/dL (26 μmol/L) except in case of hemolytic
anemia,

- Serum Creatinine ≤ 2 mg/dL (177 μmol/L) or calculated Creatinine Clearance
(Cock-croft-Gault formula) of ≥ 50 mL /min

7. Adequate bone marrow reserve :

- Absolute neutrophil count (ANC) ≥ 1 G/L (1,000 cells/mm³)

- Platelets count ≥ 50 G/L

- Hemoglobin ≥ 9.0 g/dL,

8. Signed and date informed consent,

9. Life expectancy of ≥ 90 days (3 months)

Exclusion Criteria:

1. Other types of lymphomas, e.g. B-cell lymphoma,

2. Contraindication to any drug contained in the three chemotherapy regimens (R-CHOP,
R-FC, R-DHA),

3. Tested positive for HIV,

4. Active Hepatitis B and/or C,

5. Exhibits evidence of other clinically significant uncontrolled condition(s)
including, but not limited, to active systemic fungal infection, diagnosis of fever
and neutropenia,

6. Any serious active disease or co-morbid medical condition (according to
investigator's decision),

7. Any serious medical condition, laboratory abnormality, or psychiatric illness that
would prevent the subject from signing the informed consent form,

8. Received a biological agent for anti-neoplastic intent within 30 days prior to the
first dose of study drug,

9. Use of any standard or experimental anti-cancer drug therapy within 30 days prior to
the first dose of study drug,

10. Prior history of malignancies other than lymphoma (except for basal cell or squamous
cell carcinoma of the skin or carcinoma in situ of the cervix or breast) unless the
subject has been free of the disease for ≥ 3 years,

11. Left Ventricular Ejection Fraction < 45% (calculated by echocardiographic or
scintigraphic method),

12. Pregnancy or breast feeding women,

13. Women of childbearing potential who not willing to use an adequate method of birth
controls for the duration of the study and for twelve months after the end of
treatment,

14. Male patient whose sexual partner(s) are WOCBP who are not willing to use adequate
contraception, during the study and for twelve months after the end of treatment.